DARA Biosciences Inc (NASDAQ:DARA)’s shares dropped 15.97% to $1.83. The company on May 15 announced its support for Neuropathy Awareness Week which is being observed during the week of May 12, 2014 and sponsored in the U.S. by The Neuropathy Association (www.neuropathy.org). DARA Biosciences Inc (NASDAQ:DARA), weekly performance is 49.53%. On last trading day company shares ended up $1.60. Analysts mean target price for the company is $2.00. DARA Biosciences Inc (NASDAQ:DARA), distance from 50-day simple moving average (SMA50) is -24.59%.
On May 28, 2014, CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, announced updated results from its ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating theefficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas (STS). CytRx Corporation (NASDAQ:CYTR), fell 5.33% in last trading session and ended the day on $3.91. CYTR, return on assets is -146.40%. CytRx Corporation (NASDAQ:CYTR), quarterly performance is -36.63%.
Equities researchers at Stifel Nicolaus lowered their price target on shares of OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI), from $21.00 to $9.00 in a research report issued on Tuesday,StockRatingsNetwork reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ price objective suggests a potential upside of 131.96% from the company’s current price. OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI), shares moved down 5.34% in last trading session and was closed at $3.90, while trading in range of $3.87 – 4.27. OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI), year to date (YTD) performance is -53.24%.
On May 12, 2014, Recro Pharma Inc (NASDAQ:REPH), reported financial results for the first quarter ended March 31, 2014. For the first quarter of 2014, Recro Pharma reported a net loss applicable to common shareholders of $6.4 million, or $3.67 per share, compared to a net loss of $0.5 million, or $3.30 per share, for the comparable period in 2013. Research and development expenses for the first quarter of 2014 were $0.2 million, compared to $0.1 million for the same period in 2013. Recro Pharma Inc (NASDAQ:REPH), ended the last trading day at $6.02. Company weekly volatility is calculated as 6.76%. Recro Pharma Inc (NASDAQ:REPH), showed a negative weekly performance of 9.75%.